These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9724072)

  • 1. Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements.
    Siekmann L; Siekmann A; Bidlingmaier F; Brill K; Albring M
    Eur J Endocrinol; 1998 Aug; 139(2):167-77. PubMed ID: 9724072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
    Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
    Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.
    Kuhnz W; Back D; Power J; Schütt B; Louton T
    Horm Res; 1991; 36(1-2):63-9. PubMed ID: 1839986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.
    Kuhnz W; Pfeffer M; al-Yacoub G
    J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design.
    Kuhnz W; Hümpel M; Schütt B; Louton T; Steinberg B; Gansau C
    Horm Res; 1990; 33(1):40-4. PubMed ID: 2142930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.
    Lüdicke F; Gaspard UJ; Demeyer F; Scheen A; Lefebvre P
    Contraception; 2002 Dec; 66(6):411-5. PubMed ID: 12499033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.
    Baisini O; Benini F; Petraglia F; Kuhnz W; Scalia S; Marschall HU; Brunetti G; Tauschel HD; Lanzini A
    Eur J Clin Pharmacol; 2004 Sep; 60(7):481-7. PubMed ID: 15289960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive.
    Heuner A; Kuhnz W; Heger-Mahn D; Richert K; Hümpel M
    Adv Contracept; 1995 Sep; 11(3):207-25. PubMed ID: 8533624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.